Champions Oncology Extends Convertible Debt Financing

Hackensack, NJ – March 2, 2015 – Champions Oncology, Inc. (CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 30 day extension on the $2 million convertible promissory notes with two of its executive officers executed on December 1, 2014.

Dr. David Sidransky, chairman of the board of directors remarked, “Champions continues to benefit from the confidence and commitment of our two senior executives. This note, from the CEO and President, was put in place to give the company time to optimize its cash position. Our goal remains a strong balance sheet that provides the company with the necessary capital to build the technology platform, grow our revenue and cashflow, and uplist to a national exchange. We have made great progress in the last 90 days in accomplishing this goal and expect this process to be completed shortly.”

The notes will continue to bear interest at 12% per annum and have a term of 30 days. The notes, including any accrued but unpaid interest, are convertible at the option of each noteholder : (a) upon the closing of any equity financing that occurs during the term of the notes, into the securities offered in the financing to other investors at a 5% discount to the price per share paid by other investors in the financing; and (b) upon the maturity date of the notes, into the Company’s common stock at the volume weighted average closing price of the common stock for the five trading days prior to such conversion.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions’ Personalized Oncology Solutions business. For more information, please visit

This press release may contain “forward-looking statements” (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as “believe,” “may,” “could,” “will,” “intend,” “expect,” “anticipate,” “plan,” and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology’s Form 10-K for the fiscal year ended April 30, 2014 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology’s future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology’s expectations, except as required by law.